Proposed Bayer Roundup Settlement Could Stall Thousands of Cancer Claims
Bayer’s effort to finalize a proposed $7 billion settlement tied to Roundup cancer lawsuits could face delays as legal disputes continue around how the claims should be handled in court.
The legal fight comes as the U.S. Supreme Court weighs issues connected to whether some state-law failure-to-warn lawsuits against Bayer can proceed. The company has spent years defending Roundup, a weedkiller alleged in thousands of lawsuits to cause cancer. Bayer has denied that glyphosate, Roundup’s active ingredient, causes cancer.
Subscribe free for daily political analysis they won’t broadcast. Join 110K+ readers →
The proposed settlement is designed to manage future claims while limiting prolonged litigation exposure, but legal wrangling involving bankruptcy-style protections and state court authority may slow the process and leave uncertainty for plaintiffs waiting for payouts or case resolutions.
The broader dispute matters because it could influence how large corporations handle mass-tort settlements tied to health allegations. It also affects Bayer’s long-running attempt to reduce legal pressure tied to Roundup claims that have already cost the company billions of dollars.
Subscribe free for daily political analysis they won’t broadcast. Join 110K+ readers →